Factors to consider during pulmonary drug development
Respiratory diseases severely affect the quality of life of millions and is one of the major causes
of death worldwide. In 2013, lung disease accounted for 400,000 deaths in the EU, equivalent
to 8% of the total mortality figure.
Common respiratory diseases include asthma, chronic obstructive pulmonary disease and idiopathic
pulmonary fibrosis. Such diseases compromise patient lifestyle and require effective treatment.
Get your copy of our insightful infographic today to check you're considering these factors during pulmonary drug development.